Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 387 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: albuterol/salbutamol Clear all
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

NCT02513160
View directory record Official record
Conditions
Persistent Asthma
Interventions
Beclomethasone Dipropionate 640, Placebo, Beclomethasone dipropionate via 320 mcg BAI, albuterol/salbutamol, Beclomethasone dipropionate via 320 mcg MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
75
States / cities
Peoria, Arizona • Downey, California • Huntington Beach, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)

NCT01290874
View directory record Official record
Conditions
Asthma
Interventions
Tiotropium, Salmeterol, Formoterol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
1,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
13
States / cities
Jacksonville, Florida • Marietta, Georgia • Newton, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

Treating Exacerbations of Asthma With Oral Montelukast in Children

NCT05819541
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Montelukast Oral Granules, Albuterol, Corticosteroid
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
4 Years to 12 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 29, 2026, 5:46 PM EDT
Not yet recruiting Phase 4 Interventional

Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)

NCT07721922
View directory record Official record
Conditions
COPD Exacerbation
Interventions
Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline), Albuterol sulfate, Ipratropium Bromide
Drug · Other
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 29, 2026, 5:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

NCT01799538
View directory record Official record
Conditions
Lymphangioleiomyomatosis
Interventions
albuterol inhaler, albuterol nebulizer, PFT
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Early Phase 1 Interventional

New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)

NCT02826343
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Xenon129 MRI imaging, Gadolinium MRI, Advair (250mcg/50mcg) one puff twice a day
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 3 Interventional

A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.

NCT00274534
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Salmeterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Hines, Illinois • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol

NCT00325767
View directory record Official record
Conditions
Mucociliary Clearance
Interventions
nebulized albuterol (2.5 mg/3ml/dose), nebulized levalbuterol (1.25 mg/3ml/dose), nebulized placebo (3ml/dose)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2006 · Synced Sep 29, 2026, 5:46 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acoustic Waveform Respiratory Evaluation

NCT06512064
View directory record Official record
Conditions
Asthma, COPD, Cystic Fibrosis, Ciliary Motility Disorders, Bronchiectasis, Airway Malacia, Healthy Control
Interventions
AWARE
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
8 Years to 70 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

NCT02528214
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo, Oral corticosteroid therapy (prednisone/prednisolone), Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Rolling Hills Estates, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients

NCT01899144
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Spiromax, ProAir HFA, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

NCT04655170
View directory record Official record
Conditions
COPD Exacerbation
Interventions
Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

NCT02414854
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
116
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 29, 2026, 5:46 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Nebulized Albuterol for Congestive Heart Failure Exacerbation

NCT01375361
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Albuterol, Normal Saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

NCT00846586
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler in Subjects With Asthma

NCT03643874
View directory record Official record
Conditions
Asthma
Interventions
Halix albuterol 90 mcg, albuterol HFA MDI 90 mcg
Drug
Lead sponsor
Concentrx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

NCT00808288
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive
Interventions
PF- 00610355, Placebo, Salmeterol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
30
States / cities
Fairhope, Alabama • San Diego, California • Spring Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

NCT00355342
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
37
States / cities
Berkeley, California • Fullerton, California • Rancho Mirage, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 29, 2026, 5:46 PM EDT
Withdrawn Not applicable Interventional

Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children

NCT02458482
View directory record Official record
Conditions
Asthma
Interventions
AccuPAP, Albuterol and Ipratropium Continuous Nebulizer
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478696
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
42
States / cities
Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 3 Interventional

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

NCT00064415
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions
arformoterol, Salmeterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
90
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

NCT01117116
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate and salmeterol, budesonide and formoterol
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00622635
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 300 μg, Placebo to indacaterol, Salmeterol 50 μg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Normal, Illinois • Shawnee Mission, Kansas • Lafayette, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Sep 29, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm

NCT01111110
View directory record Official record
Conditions
Asthma
Interventions
anti-static then static, Static then anti-static chamber
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 29, 2026, 5:46 PM EDT